News

TGA Consultative Committee Communique

The Therapeutic Goods Administration Consultative Committee has released the communique from the November 2024 meeting, with issues discussed including medicinal cannabis.

The Therapeutic Goods Administration Consultative Committee meets twice a year to discuss key activities and reforms being led by the TGA with stakeholders including the AMA with AMA Federal Councillor Dr Michael Bonning attending the November meeting.At the meeting, the AMA raised the issue of medicinal cannabis and the issues with direct-to-consumer telehealth models at the meeting. This is an issue the AMA has discussed with the TGA and with Ahpra and the Medical Board on many occasions over the past year. The AMA was pleased to hear that the TGA, along with a joint regulatory group, has been making progress and intends to continue regulatory action in 2025. The AMA advised that this is an important issue for AMA members and that we will remain engaged with the TGA on potential reforms, such as limiting the prescription of category 5 THC products.

Other issues discussed included vaping reforms, the use of artificial intelligence in health care, and medicine shortage reforms. The next meeting will occur in mid-2025.

Related Download

Related topics